114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study

C. Jackisch,S-A. Im,A. Mattar, R. Colomer Bosch,D. Stroyakovskiy,Z. Nowecki,M. De Laurentiis,J-Y. Pierga,K.H. Jung, C. Schem, S.H. Heeson, V. Craine, B. Wang,E. Restuccia,A.R. Tan

ESMO Open(2024)

Cited 0|Views5
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined